All In Biotech

Drug Trial Radar · NCT02480894

A Open-label, Drug-Drug Interaction With Maraviroc (DDI)

A Phase 1, Open-label, Drug-drug Interaction Study Between BMS-663068 and Maraviroc in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Sep 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

112

Actual

Start

Jul 7, 2015

Primary completion

Sep 21, 2015

Study completion Sep 21, 2015

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Jun 25, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, single sequence, two-way interaction study in healthy male and female subjects. For the effect of maraviroc on the pharmacokinetics (PK) of BMS-626529 (the active moiety of BMS-663068), there is no formal hypothesis to be statistically tested. The purpose of this assessment is to estimate the effect of maraviroc on the PK of BMS-626529 when coadministered in healthy subjects. For the effect of BMS-663068 on the PK of maraviroc, the hypothesis to be statistically tested is that BMS-663068 will not have a clinically significant effect on the PK of maraviroc when coadministered in healthy subjects.

Conditions

  • Infection, Human Immunodeficiency Virus

Interventions

  • BMS-663068Drug

    BMS-663068

  • MaravirocDrug

    Maraviroc

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. BMS-626529 Pharmacokinetics: maximum observed plasma concentration (Cmax)Time frame: predose and up to 12 hours post dose on Days 4, 16, 17, and 18
  2. BMS-626529 Pharmacokinetics: area under the plasma concentration-time curve (AUC) in a single dosing interval AUC(TAU)Time frame: predose and up to 12 hours post dose on Days 4, 16, 17, and 18
  3. Maraviroc Pharmacokinetics: CmaxTime frame: predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18
  4. Maraviroc Pharmacokinetics: AUC(TAU)Time frame: predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.